Date: 2015-09-03
Type of information: Nomination
Compound:
Company: Acadia Pharmaceuticals (USA - CA)
Therapeutic area: CNS diseases - Neurological diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 3, 2015, Acadia Pharmaceuticals announced that its Board of Directors has appointed Steve Davis as President and Chief Executive Officer. Mr. Davis has been serving as Acadia’s Interim Chief Executive Officer since March 2015. Mr. Davis has also been appointed to the Acadia Board of Directors. Steve Davis joined Acadia in July 2014 as Executive Vice President, Chief Financial Officer and Chief Business Officer and was appointed Interim Chief Executive Officer in March 2015. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics,, Executive Vice President and Chief Operating Officer at Ardea Biosciences, and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. He also recently served on the boards of directors of Synageva BioPharma, Heron Therapeutics, and Furiex Pharmaceuticals.
Financial terms:
Latest news:
